Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lessened its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 3.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,212,377 shares of the company’s stock after selling 71,241 shares during the period. Geode Capital Management LLC owned about 0.98% of Gossamer Bio worth $2,183,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. grew its holdings in Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after acquiring an additional 442,895 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after acquiring an additional 74,920 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Gossamer Bio during the 3rd quarter worth approximately $67,000. US Bancorp DE acquired a new position in Gossamer Bio during the 3rd quarter worth approximately $39,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Gossamer Bio by 26.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Up 1.8 %

Shares of Gossamer Bio stock opened at $1.11 on Wednesday. The stock has a market cap of $251.53 million, a price-to-earnings ratio of -3.47 and a beta of 1.81. The company has a fifty day simple moving average of $0.82 and a 200-day simple moving average of $0.91. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a 12-month low of $0.50 and a 12-month high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, equities analysts forecast that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.